Bimeda and Ceva Animal Health Announce Agreement on Equine Products

Bimeda, Inc. has acquired the marketing rights to Ceva Animal Health, LLC’s portfolio of equine products in the United States. The U.S. portfolio comprises Tildren (tiludronate disodium, NADA# 141-420), altrenogest (ANADA# 200-481), ConfidenceEQ, and PentosanEQ. Bimeda also acquired the marketing rights for Tildren in Canada. 

“This agreement is a key milestone in Bimeda’s strategic expansion into the Equine market. With a large portfolio of complementary products, Bimeda will now be in a strong position to serve the needs of equine customers in North America,” said Alan Kelly, Director of Commercial Development for Bimeda North America. 


Founded in Ireland in the late 1960s, Bimeda is an international developer, manufacturer and marketer of veterinary pharmaceuticals and animal health products. In addition to distributing Bimeda branded products in over seventy countries world-wide, Bimeda also manufacture private labeled products for distributors, agents and international companies. Bimeda has 9 manufacturing facilities based in Ireland, UK, Canada, US, Brazil and Kenya. The company’s headquarters are in Dublin, Ireland. For more information on Bimeda, visit

Ceva Animal Health 

Ceva Animal Health offers a growing line of products to meet the health needs of companion animals, poultry, and swine. The company’s North American headquarters are located in Lenexa, Kansas. To learn more visit

Trending Articles
Four Texas Horses Positive for EIA
EIA Confirmed in British Columbia Horse
Purebred stallion in bandages standing on pasturage. Multicolored exterior image
Research Spotlight: Sudden Death in Horses
Floor Plan Design for Small and Large Equine Hospitals promo image
Floor Plan Design for Small and Large Equine Hospitals

"*" indicates required fields

Get the best from EquiManagement delivered straight to your inbox once a week! Topics include horse care, disease alerts, and vet practitioner updates.

Additional Offers

This field is for validation purposes and should be left unchanged.